文献速递炎症性肠病

维得利珠单抗两种静脉方案治疗肛周瘘管型克罗恩病的疗效与安全性:ENTERPRISE研究

Efficacy and Safety of 2 Vedolizumab Intravenous Regimens for Perianal Fistulizing Crohn's Disease: ENTERPRISE Study.
PubMed 文献 · Clin Gastroenterol Hepatol · 2021-09-29

ENTERPRISE是一项随机双盲4期试验,评估维得利珠单抗两种静脉方案(标准方案 vs 第10周额外加一剂)治疗肛周瘘管型克罗恩病。因招募困难提前终止,32例患者中28例有基线引流瘘管,第30周53.6%患者引流瘘管减少≥50%、42.9%完全闭合,两方案疗效无明显差异,安全性与其他研究一致。

要点

  • 维得利珠单抗治疗肛周瘘管型CD可快速持续闭合瘘管,第30周完全闭合率42.9%。
  • 第10周额外加一剂维得利珠单抗未改变治疗结局。
  • 安全性与其他维得利珠单抗研究一致,未发现新安全信号。

核心结论

  • 两种维得利珠单抗静脉方案均观察到肛周瘘管型克罗恩病的持续改善。
  • 第10周额外加一剂维得利珠单抗似乎不改变治疗结局。
  • 安全性与其他维得利珠单抗研究一致。

研究设计与样本

  • 随机、双盲、4期试验(ENTERPRISE),评估两种维得利珠单抗静脉方案治疗瘘管型克罗恩病。
  • 患者接受维得利珠单抗300 mg静脉输注于第0、2、6、14、22周(VDZ组),或相同方案加第10周额外一剂(VDZ+wk10组)。
  • 因招募困难提前终止入组;分析为描述性。
  • 32例患者有基线MRI至少1个活动性肛周瘘管且基线上有瘘管愈合评估,其中28例(每组14例)基线临床检查有至少1个引流瘘管。

主要发现

  • 第30周,53.6%患者引流瘘管减少≥50%(VDZ组64.3%,VDZ+wk10组42.9%)。
  • 第30周,42.9%患者实现100%瘘管闭合(VDZ组50.0%,VDZ+wk10组35.7%)。
  • 第30周,克罗恩病活动指数和肛周疾病活动指数评分平均(标准差)分别下降51.1(78.3)和4.1(3.3)。
  • 健康相关生活质量在整个研究期间改善。
  • 未观察到新的安全信号。

临床怎么用

  • 维得利珠单抗可用于肛周瘘管型克罗恩病,标准方案与第10周加量方案疗效无明显差异。
  • 治疗期间应评估瘘管引流情况、疾病活动度、MRI及生活质量。

局限性

  • 因招募困难提前终止入组,样本量小(28例有基线引流瘘管),分析为描述性。
  • 结果需更大样本研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Fistulizing Crohn's disease (CD) is challenging to treat. We report results from ENTERPRISE, a randomized, double-blind, phase 4 trial evaluating 2 vedolizumab intravenous dosing regimens in patients with fistulizing CD. METHODS: Patients with moderately to severely active CD and 1-3 active perianal fistulae (identified on magnetic resonance imaging [MRI]) received vedolizumab 300 mg intravenously at weeks 0, 2, 6, 14, and 22 (VDZ) or the same regimen plus an additional vedolizumab dose at week 10 (VDZ + wk10). Reduction from baseline in draining perianal fistulae and disease activity, MRI assessments, health-related quality of life (HRQoL), and safety were evaluated. Enrollment was stopped prematurely because of recruitment challenges; analyses are descriptive. RESULTS: Of 32 patients with ≥1 active fistulae at baseline per MRI and postbaseline fistulae healing assessment, 28 (14 per dosing regimen) had ≥1 draining fistulae at baseline (assessed by gentle finger compression during clinical exam). Rapid and sustained fistula closure was observed; 53.6% (VDZ, 64.3%; VDZ + wk10, 42.9%) and 42.9% (VDZ, 50.0%; VDZ + wk10, 35.7%) of patients achieved ≥50% decrease in draining fistulae and 100% fistulae closure, respectively, at week 30. Mean (standard deviation) CD and Perianal Disease Activity Index scores decreased by 51.1 (78.3) and 4.1 (3.3), respectively, at week 30. HRQoL improved throughout the study. No new safety signals were observed. CONCLUSIONS: Sustained improvements in fistulizing CD were seen with both vedolizumab regimens. An additional dose at week 10 does not appear to alter treatment outcomes. Safety profile was consistent with other vedolizumab studies. CLINICALTRIALS: gov no: NCT02630966; EudraCT: 2015-000852-12.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Schwartz DA, Peyrin-Biroulet L, Lasch K, et al. Efficacy and Safety of 2 Vedolizumab Intravenous Regimens for Perianal Fistulizing Crohn's Disease: ENTERPRISE Study. Clin Gastroenterol Hepatol. 2021. PMID: 34597729. doi:10.1016/j.cgh.2021.09.028

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。